ABBV Acquires APGE
AbbVie is acquiring Apogee for $135.11 per share in cash to expand its pipeline of clinical-stage candidates for inflammatory and immunological diseases
AbbVie To Acquire Apogee And Its Diverse Pipeline Of Multiple Clinical-Stage Candidates In Development Across Inflammatory And Immunological Diseases For $135.11/Shr In Cash